Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

导出原文传递

翻译打印收藏纠错

作者： Blonde, Lawrence ^[1] ; Bailey, Timothy S. ^[2] ; Chao, Jason ^[3] ; Dex, Terry A. ^[4] ; Frias, Juan Pablo ^[5] ; Meneghini, Luigi F. ^[6] ; Roberts, Michelle ^[7] ; Aroda, Vanita R.

作者单位： Sanofi US Inc, Bridgewater, NJ USA ^[1] UT Southwestern Med Ctr, Dallas, TX USA ^[2] AMCR Inst Inc, Escondido, CA USA ^[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA ^[4] Ochsner Med Ctr, Dept Endocrinol, New Orleans, LA 70115 USA ^[5] Xinyi Inc, Bridgewater, NJ USA ^[6] Natl Res Inst, Los Angeles, CA USA ^[7]

关键词 GLP-1 RA Glycemic control Hypoglycemia Insulin dose Type 2 diabetes

发布时间 2020-03-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交